Rate of myocarditis higher after receipt of mRNA-1273, particularly for younger men (younger than 40 years)
COVID-19 mRNA Vaccines Tied to Higher Risk for Myocarditis, Pericarditis
Authors say benefits of vaccination still outweigh risks, but some individuals should be aware of their higher risk
Cardiovascular Events Up for Individuals Hospitalized With COVID-19
Largest effect sizes seen for venous thromboembolism, heart failure, and stroke; risks highest in first 30 days
Mortality Disparities by Education Widened in the U.S. in 2020
Considerable increases in disparities seen for heart disease, cancer, cerebrovascular disease, unintentional injury mortality from 2019 to 2020
Wait Times for Pediatric Heart Transplants Longer During Pandemic
Despite longer waiting list times, graft and recipient survival maintained and waiting list mortality unchanged
Risk for Myocarditis Low After BNT162b2 Booster in Israel
Risk estimates (cases per 100,000) 6.44 and 5.21 for males aged 16 to 19 and 20 to 24 years, respectively, compared with 1.42 overall
For Many, Myocarditis Risk Higher After SARS-CoV-2 Infection Than Vaccination
But myocarditis risk higher after vaccination for men younger than age 40 years, particularly after second dose of mRNA-1273
Adenoviral-Based COVID-19 Vaccines May Up Short-Term CV Risk
Increased incidence of myocardial infarction, pulmonary embolism seen in second week after first dose of Oxford-AstraZeneca vaccine
Cardiovascular Complications of COVID-19 in Pregnancy Reviewed
Cardiovascular complications, such as myocardial injury, arrhythmias, and heart failure, may require change in pregnancy management
Evidence Updated on Myocarditis After mRNA COVID-19 Vaccination
Incidence of myocarditis probably higher after vaccination with mRNA-1273 versus BNT162b2, lower with increased interval between doses